New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA

Chemico-Biological Interactions

Volumn 145, Issue 3, 2003, Pages 349-358

  Haj, Hayet Tayeb Bel ^a   Salerno, Milena ^a   Priebe, Waldemar ^b   Kozlowski, Henryk ^a,c   Garnier Suillerot, Arlette ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

Bisdaunorubicin; Circular dichroism; Daunorubicin; DNA; Nucleus

Indexed keywords

AMINO ACID; AMINOSUGAR; ANTHRACYCLINE ANTIBIOTIC AGENT; BENZYL DERIVATIVE; BISDAUNORUBICIN; DAUNORUBICIN; NAKED DNA; UNCLASSIFIED DRUG; WP 631; WP 700; WP 755; WP 756; WP 757; WP 758; WP 776; WP 784; WP 785;

ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CANCER CELL CULTURE; CELL NUCLEUS; CELL STRAIN K 562; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG BINDING; FLUORESCENCE; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; STEADY STATE; STOICHIOMETRY;

EID: 0038666523     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(03)00061-9     Document Type: Article

References (23)

1. Arcamone F. Doxorubicin, Anticancer Antibiotics. Medical Chemistry Series. 17:1981;Academic Press, New York.
2. Valentini L., Nicoletta V., Vannini E., Menozzi M., Penco Arcamone F. Association of anthracycline derivatives with DNA: a fluorescence study. Il Farmaco. 40:1985;377-390.
3. Priebe W. Mechanism of action-governed design of anthracycline antibiotics: turn-off/turn-on approach. Curr. Pharm. Des. 1:1995;51-68.
4. Gao Y.-G., Wang A.H.-J. Influence of aglycone modifications on the binding of anthracycline drugs to DNA: the molecular structure of idarubicin and 4-O-demethyl-11-deoxydoxorubicin complexed to d(CGATCG). Anti-Cancer Drug Des. 6:1991;137-149.
5. Wang A.H.-J., Ughetto G., Quigley G.J., Rich A. The interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 12 A resolution. Biochemistry. 26:1987;1152-1163.
6. Frederick C.A., Williams L.D., Ughetto G., van der Marel G.A., van Boom J.H., Rich A., Wang A.H.-J. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 29:1990;2538-2549.
7. Robinson H., Priebe W., Chaires J.B., Wang A.H.-J. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Biochemistry. 36:1997;8663-8670.
8. Leng F., Priebe W., Chaires J.B. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry. 37:1998;1743-1753.
9. Hu G.G., Shui X., Leng F., Priebe W., Chaires J.B., Williams L.D. Structure of a DNA-bisdaunomycin complex. Biochemistry. 36:1997;5940-5946.
10. Chaires J.B., Leng F., Przewloka T., Fokt I., Ling Y.-H., Perez-Soler R., Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J. Med. Chem. 40:1997;261-266.
11. Samori B., Rossi A., Domini I., Pallerano H., Marconi G., Valentini L., Gioia B., Vigevani A. Interactions between drugs and nucleic acids. Part 1. Dichroic studies of doxorubicin, daunorubicin, and their basic chromophore, quinizarin. J. Chem. Soc. Perkin Trans. 2:1987;1419-1426.
12. Gallois L., Fiallo M., Garnier-Suillerot A. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. Biochim. Biophys. Acta. 1370:1998;31-40.
13. Fiallo M., Dreschsel H., Garnier-Suillerot A., Matzanke B.F., Kozlowski H. Solution structure of the iron(III)-anthracycline complexes. J. Med. Chem. 42:1999;2844-2851.
14. Garnier-Suillerot A. Anthracycline and anthracenedione based anticancer agents. Lown J.W. Bioactive Molecules. 6:1988;121-162 Elsevier, Amsterdam.
15. Fiallo M., Tayeb H., Suarato A., Garnier-Suillerot A. Circular dichroism studies on anthracycline antitumor compounds. Relation between the molecular structure and the spectroscopic data. J. Pharm. Sci. 87:1998;967-975.
16. Priebe W., Van N.T., Burke T.G., Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs. 4:1993;37-48.
17. Lozzio C.B., Lozzio B.B. Human chronic myelogeneous leukemia cell line positive Philadelphia chromosome. Blood. 45:1975;321-334.
18. Frezard F., Garnier-Suillerot A. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. Biochim. Biophys. Acta. 1036:1990;121-127.
19. Mankhetkorn S., Dubru F., Hesschenbrouck J., Fiallo M., Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol. Pharmacol. 49:1996;532-539.
20. Marbeuf-Gueye C., Broxterman H., Dubru F., Priebe W., Garnier-Suillerot A. Kinetics of anthracycline efflux from MRP overexpressing small cell lung cancer cells. Mol. Pharmacol. 53:1998;141-147.
21. Beraldo H., Garnier-Suillerot A., Tosi L. Cu(II)-adriamycin complexes. A circular dichroism and resonance Raman study. Inorg. Chem. 22:1983;4117-4122.
22. Henry N., Fantine O., Bolard J., Garnier-Suillerot A. Interaction of adriamycin with negatively charged model membranes: evidence of two types of binding sites. Biochemistry. 24:1985;7085-7092.
23. Guano F., Pourquier P., Tinelli S., Binaschi M., Bigioni M., Animati F., Manzini S., Zunino F., Kohlhagen G., Pommier Y., Capranico G. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol. Pharmacol. 56:1999;77-84.